 Tamoxifen
"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
| Descriptor ID |
D013629
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900
|
| Concept/Terms |
Soltamox- Soltamox
- Savient brand of Tamoxifen Citrate
ICI-46474- ICI-46474
- ICI 46474
- ICI46474
- ICI-46,474
- ICI 46,474
- ICI46,474
|
Below are MeSH descriptors whose meaning is more general than "Tamoxifen".
Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".
This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 2 | 0 | 2 | | 1982 | 0 | 1 | 1 | | 1983 | 1 | 2 | 3 | | 1984 | 1 | 0 | 1 | | 1985 | 0 | 3 | 3 | | 1986 | 0 | 1 | 1 | | 1987 | 0 | 1 | 1 | | 1988 | 0 | 2 | 2 | | 1989 | 1 | 1 | 2 | | 1990 | 0 | 1 | 1 | | 1992 | 1 | 1 | 2 | | 1993 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 2 | 2 | 4 | | 1997 | 3 | 0 | 3 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 2 | 3 | | 2000 | 1 | 2 | 3 | | 2001 | 2 | 2 | 4 | | 2002 | 1 | 0 | 1 | | 2003 | 2 | 2 | 4 | | 2004 | 3 | 3 | 6 | | 2005 | 0 | 2 | 2 | | 2006 | 3 | 1 | 4 | | 2007 | 0 | 1 | 1 | | 2008 | 2 | 3 | 5 | | 2009 | 1 | 1 | 2 | | 2010 | 3 | 2 | 5 | | 2011 | 7 | 2 | 9 | | 2012 | 3 | 2 | 5 | | 2013 | 6 | 3 | 9 | | 2014 | 5 | 5 | 10 | | 2015 | 3 | 3 | 6 | | 2016 | 5 | 3 | 8 | | 2017 | 1 | 3 | 4 | | 2018 | 3 | 2 | 5 | | 2019 | 1 | 2 | 3 | | 2020 | 4 | 0 | 4 | | 2022 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
Ergun MA, Hajjar A, Alagoz O, Rampurwala M. Optimal breast cancer risk reduction policies tailored to personal risk level. Health Care Manag Sci. 2022 Sep; 25(3):363-388.
-
Semina SE, Pal P, Kansara NS, Huggins RJ, Alarid ET, Greene GL, Frasor J. Selective pressure of endocrine therapy activates the integrated stress response through NF?B signaling in a subpopulation of ER positive breast cancer cells. Breast Cancer Res. 2022 03 09; 24(1):19.
-
Mascia F, Mazo I, Alterovitz WL, Karagiannis K, Wu WW, Shen RF, Beaver JA, Rao VA. In search of autophagy biomarkers in breast cancer: Receptor status and drug agnostic transcriptional changes during autophagy flux in cell lines. PLoS One. 2022; 17(1):e0262134.
-
Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Andò S, Fuqua SAW. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
-
Bhatia S, Palomares MR, Hageman L, Chen Y, Landier W, Smith K, Umphrey H, Reich CA, Zamora KW, Armenian SH, Bevers TB, Blaes A, Henderson T, Hodgson D, Hudson MM, Korde LA, Melin SA, Merajver SD, Overholser L, Pruthi S, Wong FL, Garber JE. A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):967-974.
-
Ribi K, Luo W, Walley BA, Burstein HJ, Chirgwin J, Ansari RH, Salim M, van der Westhuizen A, Abdi E, Francis PA, Chia S, Harvey VJ, Giobbie-Hurder A, Fleming GF, Pagani O, Di Leo A, Colleoni M, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020 Jun; 181(2):347-359.
-
Kastrati I, Joosten SEP, Semina SE, Alejo LH, Brovkovych SD, Stender JD, Horlings HM, Kok M, Alarid ET, Greene GL, Linn SC, Zwart W, Frasor J. The NF-?B Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers. Mol Cancer Res. 2020 07; 18(7):1018-1027.
-
Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Di Leo A, Coates AS, Goldhirsch A, Gelber RD, Regan MM. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol. 2020 04 20; 38(12):1293-1303.
-
Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, Carrasco E, Dickler MN. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer. 2019 08; 117:91-98.
-
Goetz MP, Suman VJ, Nakamura Y, Kiyotani K, Jordan VC, Ingle JN. Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. J Clin Oncol. 2019 08 01; 37(22):1982-1983.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|